Close Menu

aneuploidy

NEW YORK (GenomeWeb) – BGI Europe and molecular diagnostics firm Genomed this week announced a partnership to offer BGI's non-invasive prenatal test in Poland.

NEW YORK (GenomeWeb) – Illumina announced after the close of the market on Friday that it is suing Ariosa Diagnostics for alleged patent infringement.

NEW YORK (GenomeWeb) – Ariosa Diagnostics has priced its planned initial public offering of 3.5 million shares.

The story has been updated to clarify that the New York State approval includes the regular Panorama panel and 22q11.2 deletion syndrome.

The story has been updated to clarify Ariosa's earnings per share for the first quarter of 2014.
NEW YORK (GenomeWeb News) – Ariosa Diagnostics' first quarter revenues more than doubled year over year, the company said in an amended Form S-1 on Wednesday.

NEW YORK (GenomeWeb News) – Sequenom said in a regulatory filing today that the US Patent and Trademark Office, Patent Trial and Appeal Board has made rulings favorable to the company in an ongoing dispute with Verinata Health regarding noninvasive prenatal testing technologies.

Researchers from the University of North Carolina's department of obstetrics and school of medicine have published a report on the center's first year offering non-invasive prenatal fetal aneuploidy tests from both Illumina-owned Verinata Health and Sequenom.

NEW YORK (GenomeWeb News) – Ariosa Diagnostics has filed a regulatory document with the US Securities and Exchange Commission for an initial public offering.

NEW YORK (GenomeWeb News) – Natera recently announced two deals for the distribution of its Panorama non-invasive prenatal test outside the US.

This article has been corrected to reflect that Illumina will seek Chinese FDA approval for a MiSeqDx-based NIPT assay, not a HiSeq2500-based assay, as previously reported.

Pages

A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.

The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.

 

University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.

In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.